Eloxatine adjuvant therapy for advanced colorectal cancer.

Published: 2005-06-27 06:55:00

Updated: 2005-06-27 06:55:00

The KFDA approved Sanofi-Aventis' Eloxatin, a colorectal cancer treatment, on June 15 for an adjuvant treatment in combination with the standard therapy after the surgical operation of advanced colorectal patient, which was the first in its new adjuvant therapy of the colorectal patients after th...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK